The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.

Amgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.

MUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.

The global antibody discovery market is projected to grow from USD 8.42 billion in 2024 to USD 17.68 billion by 2032, driven by increasing demand for targeted therapies and advancements in biologics for treating chronic diseases like cancer and autoimmune disorders.

The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.

Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response when treated with paxalisib combined with pembrolizumab and standard chemotherapy, showing a profound radiologic response in a highly aggressive cancer subtype.

Kazia Therapeutics plans to request an FDA meeting to discuss overall survival data for paxalisib, a potential treatment for glioblastoma, aiming to pursue conditional approval under the FDA's Project FrontRunner initiative.

Kazia Therapeutics reported an 86% reduction in tumor burden for a metastatic triple-negative breast cancer patient using a combination of paxalisib, immunotherapy, and chemotherapy in an expanded-access case.

The global pharmaceutical contract research organization (CRO) services market is projected to grow at a 10% CAGR, reaching USD 25 billion by 2035, driven by increasing outsourcing trends in drug discovery and development across North America and Europe.

The global drug discovery platforms market is projected to grow from $186.24 million in 2024 to $635.45 million by 2034, driven by AI, technological advancements, and increased pharmaceutical R&D investments. North America leads the market, with Asia-Pacific expected to see the fastest growth.

Sandoz plans to acquire Just-Evotec Biologics' development and manufacturing capabilities in Toulouse, France for approximately USD 300 million, aiming to strengthen its biosimilar market position and manufacturing capabilities.

The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 million in 2025, expanding at a CAGR of 10% from 2025 to 2034. The growth is driven by the rising incidence of autoimmune and cancer diseases, rising preference for outsourcing in the pharmaceutical industry, and emerging disease targets.